# Voyager Therapeutics, Inc. (VYGR) · Edgar & Edgarette company card

> Voyager Therapeutics (VYGR) saw revenue fall 49.5% in FY2025 to $40 million, operating margin -327% against a -15.8% median for biological products, (no diagnostic substances), equity 77.7% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1640266 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/VYGR) · [JSON](https://www.pops4.com/boards/company/VYGR.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $40M |
| Revenue growth, 1 year | -49.5% |
| Revenue growth per year | 1.9% |
| Operating margin | -326.6% (prior year -104.1%) |
| Net margin | -296.5% |
| Operating cash flow | −$132M |
| Capital spending | $3M |
| Free cash flow | −$135M |
| Cash | $65M |
| Long-term debt | — |
| Total assets | $252M |
| Total equity | $196M |
| Equity ÷ assets | 77.7% |
| Return on equity | -61.1% |
| Dividend per share | $0 |
| Dividend years rising | 0 |

## Readings, computed from those figures

- Altman Z: -1.03 (distress zone)
- Piotroski F: 2 of 9 (weak)
- Health Harbor boat: Rotting at the dock · four or more warning signs · slow and jumpy: growing slower than its size class, with revenue that swings more; operating cash flow was negative; operating loss: a margin of -326.6% in FY2025; revenue is hard to predict: its 80% range is ±80%
- Cash Compass: Fading · slow and jumpy, lagging its peers

## Edgarette's reading

Exposure: revenue $40.4M (FY2025). Experience: revenue down 49.5% on the year, up 1.9% a year over 4 years; operating margin -326.6%, down from -104.1%. Soundness: equity 77.7% of assets, return on equity -61.1%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $10.0M and $90.1M next year (method v4.1: its own 4-year record of growth weighed at 50% against under $50M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $8.6M to $105.3M. A statistical range, not company guidance. Against peers (31 filers, $50M+ revenue, biological products, (no diagnostic substances)): operating margin -326.6% against a -15.8% median; growth -49.5% against 21.4%.

Range logged 2026-10-22, receipt 4d44dc1f90c2216d, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 3, latest 2026-10-21 ([filing](https://www.sec.gov/Archives/edgar/data/1640266/000119312526427224/0001193125-26-427224-index.htm))

## Recent filings

- 8-K · filed 2026-11-05 · 2.01 Completion of Acquisition or Disposition of Assets · [filing](https://www.sec.gov/Archives/edgar/data/1640266/000119312526449728/0001193125-26-449728-index.htm)
- 10-Q · filed 2026-11-05 · [filing](https://www.sec.gov/Archives/edgar/data/1640266/000119312526449719/0001193125-26-449719-index.htm)
- 8-K · filed 2026-10-21 · 5.02 Departure or Election of Directors; Appointment of Officers; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1640266/000119312526427224/0001193125-26-427224-index.htm)
- 8-K · filed 2026-08-06 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1640266/000164026626000007/0001640266-26-000007-index.htm)
- 10-Q · filed 2026-08-06 · [filing](https://www.sec.gov/Archives/edgar/data/1640266/000164026626000006/0001640266-26-000006-index.htm)
- 8-K · filed 2026-07-13 · 8.01 Other Events · [filing](https://www.sec.gov/Archives/edgar/data/1640266/000110465926082906/0001104659-26-082906-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001640266.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1640266

## Cite

POPS4, Edgar & Edgarette: Voyager Therapeutics, Inc. (VYGR) company card, from the company's own SEC filings, accessed 2026-11-21, https://www.pops4.com/boards/company/VYGR. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.

